Holmusk announces closing of strategic investment from leaders in healthcare and life sciences industry
NEW YORK, December 6, 2021 / PRNewswire / – Holmusk, a leading global data science and digital health company that is building the largest real-world evidence platform (RWE) for behavioral health, has announced today the close of a strategic investment cycle. The round included new investors Novartis (dRx Capital), Northwell Holdings, the venture capital arm of Northwell Health and another leading healthcare venture capital group, as well as the initial investors Optum Ventures, Health Catalyst Capital and Heritas Capital.
The new funding round allows Holmusk to expand its global operations, as well as deepen its investment in its proprietary technology and the growth of its data asset to better leverage and analyze real-world behavioral health data to accelerate drug development and data-driven medicine.
“Holmusk is redefining the electronic health record from a simple data repository to an advanced clinical decision support tool underpinning the next generation of behavioral health evidence,” said Michael weintraub, Chairman of the Board of Directors of Holmusk. “This strategic cycle marks an exciting milestone for Holmusk as we continue to reinvent the way we care for patients with behavioral health needs.”
“Today’s news demonstrates industry validation of our real-world evidence-based behavioral health strategy with the addition of leading pharmaceutical players and vendors,” said Nawal roy, founder and CEO of Holmusk. “We are extremely fortunate to have new partners at Novartis, Northwell and others who can support our mission with their deep understanding of the importance of evidence-based care. “
Holmusk’s mission is to reinvent behavioral health and transform lives with real world evidence and digital innovation. Based in Singapore and New York, Holmusk generates evidence and creates digital solutions to advance research, innovation and care in behavioral health.
Holmusk’s flagship product NeuroBlu synthesizes real-world data (RWD) with transparent analytics tools, enabling users to create actionable insights that drive behavioral health transformation. NeuroBlu is powered by a cutting-edge and ever-evolving behavioral health clinical data set, with over 20 years of data from over half a million patients and over 20 million encounters. Holmusk uses advanced proprietary analytics to enrich data, with natural language processing and predictive disease models designed specifically for behavioral health. Holmusk enriches its data and analytics offerings with powerful digital solutions that improve patient engagement, support disease self-management, and capture patient-reported outcomes to help guide clinical decisions and analyzes. For more information, please visit www.holmusk.com.
About Northwell Holdings
Northwell Holdings is the venture capital investment arm of Northwell Health, investing in companies that are strategically synergistic with its parent company. Holdings’ mandate provides for investment capital and healthcare system expertise / access to emerging businesses that support the overall mission of advancing patient care. Northwell Health is from New York State the largest healthcare provider and private employer, with 23 hospitals, 830 ambulatory care facilities and more than 16,600 affiliated physicians.
Northwell Holdings is focused on creating new technologies and developing new ideas in the clinical and non-clinical areas of the healthcare industry. The team has extensive experience in business ventures, from starting a business and investing in start-up companies to providing strategic and advisory services to its portfolio companies.
View original content: https://www.prnewswire.com/news-releases/holmusk-announces-closing-of-strategic-investment-from-healthcare-and-life-science-industry-leaders-301437405.html